• 1.

    Waheed H, et al. Snake venom: From deadly toxins to life-saving therapeutics. Curr Med Chem 2017; 24:18741891. doi: 10.2174/0929867324666170605091546

  • 2.

    Ehrenkranz JRL, et al. Phlorizin: A review. Diabetes Metab Res Rev 2005; 21:3138. doi: 10.1002/dmrr.532

  • 3.

    Christel CM, Denardo DF. Release of exendin-4 is controlled by mechanical action in Gila monsters, Heloderma suspectum. Comp Biochem Physiol A Mol Integr Physiol 2006; 143:8588. doi: 10.1016/j.cbpa.2005.10.029

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Parkes DG, et al. Discovery and development of exenatide: The first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin Drug Discov 2013; 8:219244. doi: 10.1517/17460441.2013.741580

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Ferro EG, et al. New decade, new FDA guidance for diabetes drug development: Lessons learned and future directions. J Am Coll Cardiol 2020; 76:25222526. doi: 10.1016/j.jacc.2020.09.590

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2017; 376:891892. doi: 10.1056/NEJMc1615712

  • 7.

    Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311322. doi: 10.1056/NEJMoa1603827

  • 8.

    Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 2019; 394:121130. doi: 10.1016/S0140-6736(19)31149-3

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Tuttle KR, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018; 6:605617. doi: 10.1016/S2213-8587(18)30104-9

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Mann JFE, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017; 377:839848. doi: 10.1056/NEJMoa1616011

  • 11.

    ClinicalTrials.gov. A Research Study to See How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW). https://clinicaltrials.gov/ct2/show/NCT03819153

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    ClinicalTrials.gov. A Heart Disease Study of Semaglutide in Patients with Type 2 Diabetes (SOUL). https://clinicaltrials.gov/ct2/show/NCT03914326

  • 13.

    ClinicalTrials.gov. Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT). https://clinicaltrials.gov/ct2/show/NCT03574597

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Kanasaki K, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 2014; 63:21202131. doi: 10.2337/db13-1029

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Rosenstock J, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial. JAMA 2019; 321:6979. doi: 10.1001/jama.2018.18269

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373:232242. doi: 10.1056/NEJMoa1501352

  • 17.

    Packer M. Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials. Circ Res 2018; 122:928932. doi: 10.1161/CIRCRESAHA.118.312673

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    O’Hara DV, et al. The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes. Diabetes Obes Metab 2021; 23:763773. doi: 10.1111/dom.14281

Incretin Our Chances: Are GLP-1 Receptor Agonists the Next Big Thing in Diabetic Kidney Disease?

Susan Murray Susan Murray, MB, BAO, MRCPI, is a nephrology fellow at Duke University, Durham, NC. Matthew A. Sparks, MD, is Associate Professor of Medicine; Program Director of Nephrology Fellowship; and Lead, Society for Early Education Scholars (SEEDS) program, Department of Medicine, Duke University, and Staff Physician, Durham VA Health Care System, Durham, NC.

Search for other papers by Susan Murray in
Current site
Google Scholar
PubMed
Close
and
Matthew A. Sparks Susan Murray, MB, BAO, MRCPI, is a nephrology fellow at Duke University, Durham, NC. Matthew A. Sparks, MD, is Associate Professor of Medicine; Program Director of Nephrology Fellowship; and Lead, Society for Early Education Scholars (SEEDS) program, Department of Medicine, Duke University, and Staff Physician, Durham VA Health Care System, Durham, NC.

Search for other papers by Matthew A. Sparks in
Current site
Google Scholar
PubMed
Close
Restricted access
Save